What can you do when your myeloma medication is no longer working? Dr. Jatin Shah describes the best new approaches to overcome drug resistance and a host of treatment alternatives.
![What can you do when your myeloma medication is no longer working? Dr. Jatin Shah describes the best new approaches to overcome drug resistance and a host of treatment alternatives. image](https://healthtree.org/images-resize?width=1000&height=1000&imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fcommunity%25252Fpublic%25252Fshared%25252Fshah-jatin_0_412b15f8-2d3c-47e1-b0ec-144c3f1e513b.jpg%253Falt%253Dmedia)
What can you do when your myeloma medication is no longer working? Dr. Jatin Shah describes the best new approaches to overcome drug resistance and a host of treatment alternatives.
Event Description
Dr. Jatin Shah, MD, MD Anderson
Interview date: January 10, 2014
Dr. Shah describes his focus at MD Anderson to overcome drug resistance and provide ways to use new therapies to further expand the capacity of existing drugs that work well today in myeloma treatment. He shares several options for patients who are resistant to Revlimid and entirely different approaches for patients who are resistant to Velcade. In several instances, new drugs are being used in open studies can "reactivate" the resistant drug so that it can be used once again in treatment. He shares a large number of approaches for both newly diagnosed patients that include new and more convenient oral-based options, a non-transplant approach using the monoclonal antibody elotuzumab with a common combination (RVD), and a pre-transplant approach using this same combination (RVD) with a new drug called panobinostat that has shown promise in refractory patients. For relapsed or refractory patients, he shares the good news that the carfilzomib and pomalidomide combination has the same benefit for high-risk patients as it does for low-risk patients and a new drug called filanesib (also called ARRY-520) shows effectiveness for patients with minimal options because of drug resistance. Also for relapsed patients, he describes a early approach using a new oral PIM inhibitor called LGH447 (without steroids!) He also shares a new approach to shut down the Wnt pathway to make existing drugs more powerful and reviews the most interesting findings of ASH. With so many options, how is a patient to choose? Dr. Shah gives recommendations about how to choose a clinical trial that is the right drug, that is right for you, at the right time. He dispels myths of participating in a clinical trial and suggests how patients can become more educated to maximize the use of time with the doctor for their very best care.
The live mPatient Radio podcast with Dr. Jatin Shah
Schedule & Agenda
Speakers & Moderators
![The panelist Jatin Shah, MD](https://storage.googleapis.com/crowdnews-media-library/3442cad1-adfe-44eb-b301-b6228fd67b91.png)
Dr. Jatin Shah, M.D. is the Chief Medical Officer and Executive Vice President of Development at Karyopharm Therapeutics and has been since July of 2019. His responsibilities include the development of study protocols and clinical development plans. He prepares the regulatory documents and provides scientific and clinical input to each of the studies. Prior to that, Dr. Shah acted as Senior VP of Clinical Development and VP of Clinical Strategy at Karyopharm Therapeutics. He is the co-founder of the World Health Forum/World Myeloma Forum that was launched in February of 2017. Before those accomplishments, Dr. Shah was Director of the Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center.
![The panelist Jennifer Ahlstrom](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/community%2Fpublic%2Fshared%2FJenny%20Bio%20300x300.jpg?alt=media)
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:
![Johnson and Johnson](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FJohnson%20&%20Johnson%20Logo_64b18f59-85c9-4c20-a5ff-3842e69d8066.jpg?alt=media)
![Sanofi](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FSanofi%20updated%202023_d25a8d12-4f09-410c-9eb1-1e725b0b7c3e.jpg?alt=media)
![Pfizer](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FPfizer%20Logo%202024_50ae4587-5fdc-48e2-9a52-21651c643494.png?alt=media)
![Genentech](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/admin%2Fpublic%2Fshared%2FGenentech_Logo-700x182_e3c64168-dcf4-4540-9e9d-26500b26920a.png?alt=media)
![Regeneron](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FRegeneron_dec43aa4-fe53-4d5a-9b7f-4170101b47f9.webp?alt=media)
![Adaptive](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FAdaptive%20Logo%204.2023_e0d11d37-8b31-4c88-a0fc-4d07efc9b16b.png?alt=media)